CGTLive®’s Weekly Rewind – December 13, 2024
Review top news and interview highlights from the week ending December 13, 2024.
CGTLive®’s Weekly Rewind
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. Cilta-Cel Boosts MRD Negativity Rates Compared to Standard of Care Therapy in New Multiple Myeloma Data
The results come from patients with lenalidomide-refractory MM treated in the CARTITUDE-4 trial after 1 to 3 lines of prior therapy.
2. Manali Kamdar, MD, on the Curative Potential of Liso-Cel in Third-Line R/R LBCL
The clinical director of lymphoma services at the University of Colorado discussed 5-year follow-up data from the TRANSCEND-NHL-001 clinical trial.
3. Bendamustine Is an Effective Alternative to Fludarabine-Based Lymphodepletion in LBCL
In the wake of fludarabine shortages, lemphodepletion with bendamustine was found to be an effective alternative compared for patients with large B-cell lymphoma being treated with a CD19-directed CAR T-cell therapy.
4. Haydar Frangoul, MD, on Sickle Cell Disease Gene Therapy Exa-Cel's Ability to Prevent VOCs
The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed the latest data update from the CLIMB SCD-121 trial evaluating exa-cel.
5. Tabelecleucel Efficacy Sustained in EBV-positive PTLD, as FDA Considers Application
With an FDA deadline pending in January, tabelecleucel remained safe and effective with longer follow-up for Epstein–Barr virus-associated post-transplant lymphoproliferative disease.
Transplant Eligibility Versus CAR-T Eligibility
January 16th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.
